Abstract:Objective To investigate the impact of OPRM1 gene polymorphism on the analgesic effect of trans-dermal Fentanyl. Method 123 cancer patients with pain were enrolled in this study, and the severity of pain before and after the administration of transdermal Fentanyl was then evaluated. The dose of transdermal Fentanyl used when NRS≤3 was recorded, and the inter-patient differences of dose were compared by detecting the polymorphic sites of OPRM1 allele with polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP). Result The mutation frequency of OPRM1 was 32.9%. Of the 123 patients, 66 had mutation, in which 57 (46.34%) cases had wildtype homozygotes (A/A), 51 (41.46%) cases were with heterozygotes (A/G), and 15 (12.20%) cases had mutant homozygotes (G/G) of OPRM1. The dose of transdermal Fentanyl required for G/G patients was remarkably higher than that of A/G patients, with significant differences observed (P<0.05). While the dose requirement between A/A and A/G patients was similar (P>0.05). There was no association between OPRM1 genetic polymorphisms and inci-dences of adverse drug reactions. Conclusion OPRM1 gene polymorphism is an effective predictor in estimating the patient ’s response to transdermal Fentanyl, which provides theoretical basis for individual therapy.

The effect of OPRM1 gene polymorphism on analgesic potency of transdermal Fentanyl